Viome is combining science and AI to provide dietary advice and detect diseases. Two company execs share how they use the MVP ...

CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of ...

Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

Helius Medical Technologies (HSDT) stock surged on Wednesday after the neurotech company announced an authorized claim for payment for its Portable Neuromodulation Stimulator (PoNS) from CVS Health ...

European shares were mixed today. The eurozone's STOXX 600 fell 0.09%, while Spain's IBEX 35 Index fell 0.04%. London's FTSE ...

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of ...

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

Helius Medical Technologies (NASDAQ:HSDT) on Wednesday has priced its public offering, that includes 2,768,600 Class A common ...

Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a ...

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value ...

Helius Medical Technologies announced compliance with Nasdaq's bid price requirement while working on equity rule compliance by June 30, 2025. Helius Medical Technologies, Inc. announced that it ...

Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirementNEWTOWN, ...